Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Oct 23, 2013 3:03pm
441 Views
Post# 21842181

RE:Scoping study to be released

RE:Scoping study to be releasedJosa:

Thanks for the response..wrt the Scoping Study ETA. November is not that far away ... as is the parameters/scope for the Scoping Study.

In a fickle POG environment, a second hole could have a "double whammy" impact in that it could be both a confirmatory and expansonary.

While I will have a very low expectation of BRD indicating any SAS dealings, this is covered-off in a previous post. Point being, I'm speculating that by working with SAS (I'm also an SAS sh) BRD may get the opportunity to attain depth to UG via an adit from the SAS side in addition to the OP synergies already, "in the public domain".

In the Sage case, they're on SAS's property next to the Black Fox (old Stock) Mill .  Sage will possibly working with SAS to lobby/swap BRD for mill capacity (horse trading).. synergy here is any BRD ore displaced by Sage MAY be sent to HM (not to mention a cost engineers dream... shorter distance, a right hand turn unto the highway and another unto the HM mill with lower density traffic). SAS has surface equuipment at Hislop North which may obviate BRD's OOPS pit on a split schedule (travel time/cost for OP spread).

BWDIK? If BRD cannot come to some arrangement with SAS there could be an entitity out there (looking to mine in a predictable/stable mining environment) capable of combining both properties and extracting the potential synergies. e.g. Alamos.

Cheers
Stanley


Bullboard Posts